Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
A phase 1/2 trial of Palacaparib in prostate cancer, run by AstraZeneca, now recruiting.
Overview
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07181161 by AstraZeneca, with 283 participants planned, started 2025-10-01 and due to reach its primary completion in 2029-01-18. Interventions recorded: AZD0516, AZD9574. Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.
Setting
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer
Phase
Phase 1/2
Sponsor
AstraZeneca
Registry
Enrolled
283
Similar pages
not linked directly; found by shared links- TrialPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Shares Palacaparib, AstraZeneca, Prostate cancer.
- TrialStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Shares Palacaparib, AstraZeneca.
- TrialA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Shares Palacaparib, AstraZeneca.
- TrialPhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Shares Palacaparib, AstraZeneca.